Did oseltamivir really improve survival in critically ill patients with influenza A (H1N1) pdm09?

Clinical Infectious Diseases

Volumn 56, Issue 7, 2013, Pages 1062-

  Kadhiravan, Tamilarasu ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR;

2009 H1N1 INFLUENZA; AGE; COMORBIDITY; CRITICALLY ILL PATIENT; DIABETES MELLITUS; DRUG EFFICACY; HUMAN; INFECTION COMPLICATION; INFLUENZA VACCINATION; KIDNEY FAILURE; LETTER; MORBID OBESITY; PRIORITY JOURNAL; SURVIVAL;

ANTIVIRAL AGENTS; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE;

EID: 84875022855     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis1212     Document Type: Letter

References (8)

1. Louie JK, Yang S, Acosta M, et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A(H1N1)pdm09. Clin Infect Dis 2012; 55: 1198-204.
2. Yang SG, Cao B, Liang LR, et al. Antiviral therapy and outcomes of patients with pneumonia caused by influenza A pandemic (H1N1) virus. PLoS One 2012; 7: e29652.
3. Miller PE, Rambachan A, Hubbard RJ, et al. Supply of neuraminidase inhibitors related to reduced influenza A (H1N1) mortality during the 2009-2010 H1N1 pandemic: an ecological study. PLoS One 2012; 7:e43491.
4. Hiba V, Chowers M, Levi-Vinograd I, Rubinovitch B, Leibovici L, Paul M. Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): retrospective cohort study. J Antimicrob Chemother 2011; 66: 1150-5.
5. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2012; 1: CD008965.
6. Payne D. Tamiflu: the battle for secret drug data. BMJ 2012; 345:e7303.
7. Hernán MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis 2011; 53: 277-9.
8. Center for Drug Evaluation and Research. Food and Drug Administration. Guidance for industry: influenza: developing drugs for treatment and/or prophylaxis. April 2011. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInforma tion/Guidances/ucm091219.pdf. Accessed 10 November 2012.